Altimmune Inc. (ALT)
ALT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326190/000132619026000018/0001326190-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001326190 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $41K |
| Net income | -$88.1M |
| Operating income | -$94.5M |
| Net margin | -214861.0% |
| Operating margin | -230461.0% |
| Revenue growth | +105.0% |
| Cash | $43.8M |
| Total assets | $279.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7403.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $28.9M cash; operating cash flow -$25.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 194,589,451 (2026-11-06); 104,254,173 a year earlier; 53,728,871 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-04-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $370K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$31.6M | -$37.7M | $28.9M | $35.0M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$22.8M | -$24.2M | $63.0M | $34.7M | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$22.6M | -$20.9M | $97.6M | $34.5M | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | $26K | -$27.4M | -$19.4M | $43.8M | $34.3M | $41K | 10-K 2026-03-06 |
| Q3 2025 2025-09-30 | $5K | -$19.0M | -$11.9M | $61.2M | $14.4M | $20K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $5K | -$22.1M | -$19.4M | $183.1M | $14.3M | $20K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $5K | -$19.6M | -$16.8M | $49.1M | No debt tags | $20K | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $5K | -$23.2M | -$18.3M | $36.9M | No debt tags | $20K | 10-K 2026-03-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-24 |
| Latest annual report | 10-K | 2026-03-06 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-03-17 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.9% |
| 1 month | -32.3% |
| 3 months | -42.9% |
| Year to date | -54.4% |
| 1 year | -59.5% |
| From 52-week high | -73.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc. | $3.02 | -0.98% | $305.2M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| EBS | Emergent BioSolutions Inc. | $5.81 | +0.35% | $298.7M |
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| EVMN | Evommune Inc. | $7.10 | -6.95% | $293.6M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| AVIR | Atea Pharmaceuticals Inc. | $4.12 | -4.19% | $330.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier